Back to Search
Start Over
CD64: An Attractive Immunotherapeutic Target for M1-type Macrophage Mediated Chronic Inflammatory Diseases.
- Source :
-
Biomedicines [Biomedicines] 2017 Sep 12; Vol. 5 (3). Date of Electronic Publication: 2017 Sep 12. - Publication Year :
- 2017
-
Abstract
- To date, no curative therapy is available for the treatment of most chronic inflammatory diseases such as atopic dermatitis, rheumatoid arthritis, or autoimmune disorders. Current treatments require a lifetime supply for patients to alleviate clinical symptoms and are unable to stop the course of disease. In contrast, a new series of immunotherapeutic agents targeting the Fc γ receptor I (CD64) have emerged and demonstrated significant clinical potential to actually resolving chronic inflammation driven by M1-type dysregulated macrophages. This subpopulation plays a key role in the initiation and maintenance of a series of chronic diseases. The novel recombinant M1-specific immunotherapeutics offer the prospect of highly effective treatment strategies as they have been shown to selectively eliminate the disease-causing macrophage subpopulations. In this review, we provide a detailed summary of the data generated, together with the advantages and the clinical potential of CD64-based targeted therapies for the treatment of chronic inflammatory diseases.<br />Competing Interests: Theo Thepen and Stefan Barth are co-inventors on CD64-related patents and patent applications, which are assigned to Fraunhofer or UCT. The authors otherwise declare no conflicts of interest.
Details
- Language :
- English
- ISSN :
- 2227-9059
- Volume :
- 5
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Biomedicines
- Publication Type :
- Academic Journal
- Accession number :
- 28895912
- Full Text :
- https://doi.org/10.3390/biomedicines5030056